Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies.
The partnership will leverage Concerto HealthAI’s eurekaHealth platform, artificial intelligence (AI) models, Real World Clinical Electronic Medical Record (EMR) and healthcare claims.
It will use data from clinical practices under the American Society of Clinical Oncology’s CancerLinQ initiative and additional centres across the US.
Real-world data on patient insights is expected to enable precision treatment for solid tumours and hematologic malignancies.
Pfizer Global Product Development oncology chief development officer Chris Boshoff said: “Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes.
“We are pleased to work with Concerto HealthAI, to accelerate insights and outcomes studies that may lead to a more comprehensive understanding of patients’ experience with our medicines.”
Under the alliance, the companies will perform synthetic control arm and prospective real-world data (RWD) outcomes studies. Initial findings from the research are expected to be available early next year.
A joint steering committee will be formed to supervise the partnership.
Concerto HealthAI CEO Jeff Elton said: “This collaboration aims to find and help patients who may benefit from new therapeutic combinations.
“We are using our definitive real-world data, AI-enabled abstraction, data science expertise, and strength in outcomes research to identify new and more precise treatment options; refine study designs; and speed-up the completion times for various outcomes studies.”
Last month, Concerto HealthAI partnered with Bristol-Myers Squibb to use real-world evidence for precision oncology.
Under the multi-year deal, the partners agreed to leverage AI and machine learning to drive cancer clinical trials and obtain insights for precision therapy and better patient outcomes.